智通财经APP获悉，11月12日，CDE官网公示，强生(JNJ.US)尼卡利单抗注射液拟被纳入优先审评，适用于治疗自身抗体阳性的全身型重症肌无力(gMG)成人患者和青少年患者(大于12岁)。尼卡利单抗(Nipocalimab)是强生通过约65亿美元收 ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

Looking for the latest stock opportunities in December 2024? We have you covered. Click to read our top stock picks to ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

The first time Johnson & Johnson faced a lawsuit due to its talc-based baby powder causing cancer was way back in 1999. Since ...

On Friday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $155.47 which represents a decrease of $-1.26 or -0.80% from the prior close of $156.73. The stock opened at $157 and touched ...

Get-Up 3 will feature Brittany Howard of Alabama Shakes, Mike Cooley of Drive-by Truckers, Lee Bains and more.

强生(JNJ.US)尼卡利单抗注射液拟被纳入优先审评  快报 ...

HRSA’s threats of penalties led J&J to halt the plan, prompting a legal battle to protect its proposed changes. Johnson & ...

Julian Harrison gave his rating based on several factors surrounding Protagonist Therapeutics’ promising drug candidate, JNJ-2113. The upcoming Phase 3 trial data for JNJ-2113 in psoriasis is pivotal, ...